decisionhealth Newsletters, Part B News - 2003 Issue 9 (September)
Private payers wait on Medicare action
Subscribe or sign in to view the full article.
Article Overview
This short policy article reviews Medicare’s current approach to paying for injectable drugs under Part B and explains why private payers are watching federal payment changes closely. It is relevant for readers tracking reimbursement policy, Medicare payment reform, and how public-sector decisions can influence private payer payment models. The discussion centers on MedPAC findings, CMS proposals, and the broader market impact of changing the Medicare drug payment formula.
Why This Topic Matters
Payment policy changes for physician-administered injectable drugs can affect both Medicare reimbursement and the payment methods used by private insurers, making this topic important for billing, reimbursement, and payer-contract strategy.
What You Will Learn
- How Medicare currently pays for physician-administered injectable drugs under Part B
- Why private payers are monitoring Medicare payment reform
- What role MedPAC and CMS play in discussions about drug payment policy
- How federal reimbursement changes can influence private payer payment models
Who Should Read This
- Medical coders
- Billing staff
- Revenue cycle professionals
- Practice administrators
- Payer policy analysts
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com